ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.770
+0.010 (0.27%)
At close: Apr 28, 2026, 4:00 PM EDT
3.770
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
ADC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 81.36 | 70.84 | 69.56 | 209.91 | 33.92 | Upgrade
|
| Revenue Growth (YoY) | 14.85% | 1.84% | -66.86% | 518.89% | - | Upgrade
|
| Cost of Revenue | 107.52 | 114.06 | 129.66 | 189.76 | 159.4 | Upgrade
|
| Gross Profit | -26.16 | -43.23 | -60.1 | 20.15 | -125.48 | Upgrade
|
| Selling, General & Admin | 79.93 | 85.91 | 105.89 | 143.49 | 136.24 | Upgrade
|
| Operating Expenses | 79.93 | 85.91 | 105.89 | 143.49 | 136.24 | Upgrade
|
| Operating Income | -106.1 | -129.14 | -165.99 | -123.34 | -261.72 | Upgrade
|
| Interest Expense | -51.63 | -50.21 | -46.33 | -36.73 | -18.34 | Upgrade
|
| Interest & Investment Income | 8.81 | 12.27 | 10.54 | 2.57 | 0.07 | Upgrade
|
| Earnings From Equity Investments | - | -1.54 | -5.53 | -10.08 | -6.67 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.67 | -0.08 | -0.05 | -0.11 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 23.38 | 12.54 | 6.4 | 52.91 | 35.11 | Upgrade
|
| EBT Excluding Unusual Items | -126.2 | -156.16 | -200.95 | -114.79 | -251.51 | Upgrade
|
| Merger & Restructuring Charges | -13.12 | - | - | - | - | Upgrade
|
| Asset Writedown | -2.28 | -1.52 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -42.11 | - | Upgrade
|
| Pretax Income | -141.61 | -157.68 | -200.95 | -156.9 | -251.51 | Upgrade
|
| Income Tax Expense | 1.02 | 0.17 | 39.11 | 0.23 | -21.48 | Upgrade
|
| Net Income | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | Upgrade
|
| Net Income to Common | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | Upgrade
|
| Shares Outstanding (Basic) | 127 | 97 | 82 | 78 | 77 | Upgrade
|
| Shares Outstanding (Diluted) | 127 | 97 | 82 | 78 | 77 | Upgrade
|
| Shares Change (YoY) | 30.78% | 18.91% | 4.55% | 1.83% | 17.33% | Upgrade
|
| EPS (Basic) | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 | Upgrade
|
| EPS (Diluted) | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 | Upgrade
|
| Free Cash Flow | -141.44 | -124.7 | -121.9 | -139 | -236.81 | Upgrade
|
| Free Cash Flow Per Share | -1.11 | -1.28 | -1.49 | -1.78 | -3.09 | Upgrade
|
| Gross Margin | -32.16% | -61.02% | -86.40% | 9.60% | - | Upgrade
|
| Operating Margin | -130.41% | -182.30% | -238.63% | -58.76% | -771.65% | Upgrade
|
| Profit Margin | -175.31% | -222.83% | -345.11% | -74.86% | -678.20% | Upgrade
|
| Free Cash Flow Margin | -173.85% | -176.04% | -175.25% | -66.22% | -698.20% | Upgrade
|
| EBITDA | -105.39 | -127.8 | -164.8 | -122.28 | -260.75 | Upgrade
|
| EBITDA Margin | -129.54% | -180.42% | -236.92% | -58.26% | - | Upgrade
|
| D&A For EBITDA | 0.71 | 1.33 | 1.19 | 1.06 | 0.97 | Upgrade
|
| EBIT | -106.1 | -129.14 | -165.99 | -123.34 | -261.72 | Upgrade
|
| EBIT Margin | -130.41% | -182.30% | -238.63% | -58.76% | - | Upgrade
|
| Revenue as Reported | 81.36 | 70.84 | 69.56 | 209.91 | 33.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.